Journal Watch · Frontiers in Immunology · 2026
An endoplasmic reticulum stress- and Golgi apparatus-related signature reveals immune microenvironment remodeling and <i>MUC16</i>-driven PI3K/AKT activation in lung adenocarcinoma.
Further evidence suggested that <i>MUC16</i> may contribute to LUAD progression, at least in part, through FAK-mediated activation of PI3K/AKT signaling, supporting its potential value as a prognostic biomarker and a candidate for further therapeutic investigation.
TL;DR
Further evidence suggested that <i>MUC16</i> may contribute to LUAD progression, at least in part, through FAK-mediated activation of PI3K/AKT signaling, supporting its potential value as a prognostic biomarker and a candidate for further therapeutic investigation.
Key findings
- The prognostic performance of this signature was further supported in additional independent LUAD cohorts, and the defined risk groups differed significantly in tumor microenvironment features, immune infiltration patterns, mutational landscapes, and predicted therapeutic responses.
- Subsequent bioinformatic analyses and <i>in vitro</i> validation highlighted <i>MUC16</i> as a markedly upregulated gene in LUAD, whose higher expression was associated with poorer patient outcomes.
- Functional and mechanistic experiments further suggested that <i>MUC16</i> may promote malignant phenotypes in LUAD cells, at least in part, through FAK-mediated activation of PI3K/AKT signaling.<h4>Conclusion</h4>We developed an EGRG-based prognostic signature for LUAD, which may provide a useful reference for risk stratification and therapeutic decision-making.
- Further evidence suggested that <i>MUC16</i> may contribute to LUAD progression, at least in part, through FAK-mediated activation of PI3K/AKT signaling, supporting its potential value as a prognostic biomarker and a candidate for further therapeutic investigation.
What they did
DEGs identified in the TCGA-LUAD cohort were intersected with endoplasmic reticulum stress- and Golgi apparatus-related genes (EGRGs) to obtain differentially expressed EGRGs in LUAD. A machine learning-based prognostic signature was constructed in the TCGA-LUAD cohort and validated in external GEO datasets. Patients were stratified according to the calculated risk score, after which tumor mutational burden, immune microenvironment characteristics, and drug sensitivity were compared between risk groups. In addition, the key gene <i>MUC16</i> was further evaluated through <i>in vitro</i> experiments.<h4>Results</h4>A 17-gene prognostic signature was established based on 133 differentially expressed endoplasmic reticulum stress- and Golgi apparatus-related genes.
Full abstract (original)
Background: <h4>Background</h4>Lung adenocarcinoma (LUAD), the most prevalent histological subtype of non-small cell lung cancer (NSCLC), is characterized by substantial clinical heterogeneity and a frequent propensity to acquire resistance to targeted therapies. Accumulating evidence indicates that both endoplasmic reticulum stress and Golgi apparatus dysfunction play critical roles in reshaping the tumor microenvironment (TME). However, their coordinated contribution to LUAD progression remains poorly understood. Against this background, we developed a machine learning-based prognostic framework focused on endoplasmic reticulum stress- and Golgi apparatus-related genes (EGRGs) to improve prognostic stratification and explore their potential therapeutic implications in LUAD.<h4>Methods</h4>Publicly available transcriptomic profiles and corresponding clinical data of LUAD patients were collected from TCGA and GEO.
What they did: DEGs identified in the TCGA-LUAD cohort were intersected with endoplasmic reticulum stress- and Golgi apparatus-related genes (EGRGs) to obtain differentially expressed EGRGs in LUAD. A machine learning-based prognostic signature was constructed in the TCGA-LUAD cohort and validated in external GEO datasets. Patients were stratified according to the calculated risk score, after which tumor mutational burden, immune microenvironment characteristics, and drug sensitivity were compared between risk groups. In addition, the key gene <i>MUC16</i> was further evaluated through <i>in vitro</i> experiments.<h4>Results</h4>A 17-gene prognostic signature was established based on 133 differentially expressed endoplasmic reticulum stress- and Golgi apparatus-related genes.
Results & conclusions: The prognostic performance of this signature was further supported in additional independent LUAD cohorts, and the defined risk groups differed significantly in tumor microenvironment features, immune infiltration patterns, mutational landscapes, and predicted therapeutic responses. Subsequent bioinformatic analyses and <i>in vitro</i> validation highlighted <i>MUC16</i> as a markedly upregulated gene in LUAD, whose higher expression was associated with poorer patient outcomes. Functional and mechanistic experiments further suggested that <i>MUC16</i> may promote malignant phenotypes in LUAD cells, at least in part, through FAK-mediated activation of PI3K/AKT signaling.<h4>Conclusion</h4>We developed an EGRG-based prognostic signature for LUAD, which may provide a useful reference for risk stratification and therapeutic decision-making. Further evidence suggested that <i>MUC16</i> may contribute to LUAD progression, at least in part, through FAK-mediated activation of PI3K/AKT signaling, supporting its potential value as a prognostic biomarker and a candidate for further therapeutic investigation.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1887786 · PubMed 42774450.
Why it matters for pharma & biotech
- Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: AI in drug discovery / diagnostics
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Further evidence suggested that <i>MUC16</i> may contribute to LUAD progression, at least in part, through FAK-mediated activation of PI3K/AKT signaling, supporting its potential value as a prognostic biomarker and a candidate for further therapeutic investigation.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. DEGs identified in the TCGA-LUAD cohort were intersected with endoplasmic reticulum stress- and Golgi apparatus-related genes (EGRGs) to obtain differentially expressed EGRGs in LUAD.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1887786. PubMed ID: 42774450. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/an-endoplasmic-reticulum-stress-and-golgi-apparatus-related-signature-re-887786/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides